Purpose: To determine if BET inhibition will increase the time to MACE in high-risk patients with recent ACS, T2DM and low HDL-C.

Trial Design: Phase 3; n=2425; multi-center (185 sites, 13 countries), double-blinded, placebo-controlled trial.  High-risk patients with ACS, T2DM and low HDL-C were randomized to high-intensity statin therapy (atorvastatin or rosuvastatin) + BET inhibitor (100 mg. orally twice a day) or high-intensity statin therapy  + placebo. Average or 26.5 months follow-up.

Primary Endpoints: Time to MACE (CV death, non-fatal MI, or stroke)?

Results: Reduction in MACE with BET inhibition in this patient population did not reduce the primary endpoint significantly.